• PARP7 Inhibition Stabilizes STAT1/2 in EAE

  2026-10-01

  Xu et al. identify PARP7 as a suppressor of type I interferon signaling that ADP-ribosylates STAT1 and STAT2, promoting their ubiquitination and p62-dependent autophagic degradation. Inhibition of PARP7 restored interferon pathway activity and reduced experimental autoimmune encephalomyelitis in mice, linking a defined post-translational mechanism to disease-relevant neuroinflammation.

• Bifurcated Redox Sensing by TRPV1 and TRPA1

  2026-10-01

  The reference study shows that TRPV1 and TRPA1 distinguish singlet oxygen from hydrogen peroxide rather than responding to reactive oxygen species uniformly. By combining electrophysiology, calcium imaging, agonist-selective testing, and residue analysis, it identifies divergent channel responses with implications for mechanistic redox signaling studies.

• Bifurcated ROS Sensing by TRPV1 and TRPA1

  2026-09-30

  The reference study shows that TRPV1 and TRPA1 distinguish singlet oxygen from hydrogen peroxide through different channel-specific mechanisms. Its combination of electrophysiology, calcium imaging, agonist-selective testing, and residue analysis provides a framework for interpreting reactive oxygen species effects on ion-channel signaling.

• MK-8745: Selective Aurora A Inhibitor Workflows

  2026-09-30

  MK-8745 enables controlled studies of Aurora A–dependent mitotic arrest, tetraploidy, and apoptosis across cancer cell models. This workflow connects biochemical potency with practical experiments in p53 biology, non-Hodgkin lymphoma, retinoblastoma research, and tumor xenograft models while emphasizing formulation and interpretation controls.

• Rosiglitazone Workflow for PPARγ Metabolic Studies

  2026-09-29

  Build reproducible adipogenesis, insulin-response, and PPARG-variant rescue assays with Rosiglitazone, also known as Brl-49653. This guide connects practical dosing and controls with a recent FPLD3 study that used receptor activation to probe protein instability, mitochondrial dysfunction, and metabolic rescue.

• Carvacrol in Redox-Resolved Cell Assays

  2026-09-29

  Carvacrol is more than a TRPA1 agonist: it can help researchers separate reactive oxygen species sensing from downstream cell-fate responses. This guide translates recent channel biology into rigorous assay design for cell cycle research, apoptosis research, and mechanistic validation.

• KN-62: From CaMKII Mechanism to Translation

  2026-09-28

  KN-62 provides a focused pharmacological route to interrogate CaMKII-linked calcium signaling, secretion, metabolism, and cell-cycle phenotypes. This article connects that tool to emerging evidence that proteolytic signaling sustains social memory, while defining the controls translational researchers need before extending findings across biological domains.

• MOG (35-55): EAE Workflow and Assay Insights

  2026-09-28

  Use MOG (35-55) to establish a defined antigen challenge for experimental autoimmune encephalomyelitis (EAE) and investigate neuroinflammation in a multiple sclerosis research setting. This guide connects peptide handling and study design with recent evidence that PARP7 inhibition can alter type I interferon signaling and EAE outcomes.

• miR-18a–ALOXE3 Signaling in Glioblastoma

  2026-09-27

  The study identifies a tumor-suppressive role for ALOXE3 in glioblastoma: its loss reduces ferroptotic sensitivity and promotes migration through lipid signaling. It places miR-18a upstream of ALOXE3, outlining a molecular axis that connects microRNA regulation, cell death, and tumor behavior while leaving important questions about clinical translation unresolved.

• Autophagy, Lipid Breakdown, and Salmon Lipotoxicity

  2026-09-26

  In Atlantic salmon SHK-1 cells, rapamycin-induced autophagy was associated with lipid-droplet breakdown and reduced lipotoxic stress, while lipidomics and proteomics revealed changes in lipid storage and lipogenic proteins. The study provides a fish-cell model for investigating lipophagy and highlights why lipid composition and autophagic activity should be assessed together rather than treating total lipid abundance as the sole outcome.

• Optimizing hiPSC-Derived Functional Platelet Production

  2026-09-25

  Yue and colleagues developed an optimized differentiation scheme that shortens hiPSC-to-platelet production to 19 days while increasing reported output and lowering estimated costs. Their findings emphasize the combined effects of embryoid-body input, human platelet lysate, small-molecule substitutions, and megakaryocyte maturation on producing platelets with measurable in-vitro clot activity.

• Rosiglitazone A4304: Reliable Metabolic Assay Design

  2026-09-25

  A scenario-driven guide to using Rosiglitazone (SKU A4304) in metabolic, viability, and cytotoxicity workflows. It covers PPARγ biology, stock preparation, assay interpretation, and evidence-based product selection without treating metabolic readouts as direct measures of cell number.

• Clodronate Liposomes for In Vivo Macrophage Studies

  2026-09-24

  Use Clodronate Liposomes to test whether macrophages are necessary for an in vivo phenotype, while PBS liposomes help separate clodronate effects from liposome exposure. The workflow pairs depletion checks with functional phagocytosis assays—an important distinction when studying age-related changes in macrophage activity.

• SVP3 from Sanghuangporus vaninii: Lipid Effects

  2026-09-24

  A study in Carbohydrate Polymers characterized SVP3, a neutral hetero-galactan purified from Sanghuangporus vaninii, and found that it improved several lipid and tissue outcomes in hyperlipidemic mice. Integrated gut microbiota, serum metabolomics, and liver proteomics linked these effects to inflammation-associated TLR4/NF-κB signaling, although the findings remain preclinical and do not establish a treatment for human hyperlipidemia.

• Sodium Ascorbate Workflows for Cancer Research

  2026-09-23

  Build reproducible ROS and tumor-cell response assays with Sodium Ascorbate, from fresh stock preparation to orthogonal viability and motility readouts. The workflow keeps glioblastoma evidence distinct from an ESCC immunotherapy biomarker study, while showing how its experimental-design lessons can inform stronger assay controls.

8363 records 1/558 page Next 12345 下5页 Last page